Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.48 |
| ▸ | PARP3 | Q9Y6F1 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27171015 | 0.86 | PARP1 (0.44) | PARP1PARP2PARP3TNKS | |
| SCHEMBL16329978 | 0.85 | PARP1 (0.61) | PARP1PARP2PARP3 | |
| SCHEMBL20166686 | 0.82 | KDM4E (0.46) | PARP1PARP2PARP3ALDH1A1NR4A2 | |
| SCHEMBL20167198 | 0.81 | PARP1 (0.44) | PARP1PARP2PARP3TNKS | |
| SCHEMBL16827111 | 0.79 | PARP1 (0.44) | PARP1PARP2PARP3ALDH1A1NR4A1 | |
| SCHEMBL16827077 | 0.79 | PARP1 (0.55) | PARP1PARP2PARP3ALDH1A1NR4A1 | |
| SCHEMBL20502980 | 0.76 | JAK2 (0.44) | KDM4E | |
| SCHEMBL19029026 | 0.74 | KDM4E (0.46) | ALDH1A1HSD17B10ALOX12KDM4EHPGD | |
| SCHEMBL25207713 | 0.73 | HSD17B10 (0.42) | NR4A1HSD17B10KDM4EDHODH | |
| SCHEMBL2011238 | 0.72 | KDM4E (0.46) | ALDH1A1NR4A1NR4A2NR4A3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4232431-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116583501-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115515679-A | Heterocyclic amides and their use for modulating splicing | 雷密克斯医疗公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022083703-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2017093545-A1 | ANTI-BACTERIAL COMPOUNDS BASED ON AMINO-GOLD PHOSPHINE COMPLEXES | AUSPHERIX LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| EP-2007733-B1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-25 | — | — | EP | disclosed |
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
| EP-2822944-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN, INC. (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013134079-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-18 | — | — | US | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| EP-2007733-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113596-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | PARP1 2531/4885PARP2 2728/4885PARP3 2216/4885 |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | PARP1 1/4885PARP2 3/4885PARP3 2/4885 |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | PARP1 468/4885PARP2 875/4885PARP3 690/4885 |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | PARP1 1/4885PARP2 3/4885PARP3 2/4885 |
| US-20250154169-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | PARP1 768/4885PARP2 946/4885PARP3 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.